NEW YORK (GenomeWeb) – Orig3N, a biotechnology firm developing a disease-modeling platform targeting rare genetically inherited diseases, today announced it raised $3.1 million in a private round of financing. 

The proceeds will go toward expanding Boston-based Orig3N's Life Capsule, a bio-repository for people to contribute their cells via a blood sample. The cells are reprogrammed into induced pluripotent stem cells, which can be used for disease modeling outside the body for medical research, as well as for individualized therapy. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.